Company intelligence / Profile preview
Kubota Vision
- Ownership
- Private
- Development stage
- Preclinical
Overview
Kubota Vision develops both pharmaceuticals and medical devices focused on ophthalmology. Its lead small molecule program, emixustat hydrochloride, has completed Phase 2/Phase 3 studies targeting Stargardt disease with orphan designation from FDA and EMA. The company also develops innovative devices such as the wearable myopia-control "Kubota Glass"—which uses microLEDs to project images into the peripheral retina—and "eyeMO," a portable home-use OCT device licensed out for development/commercialization in Asia through AUROLAB.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculeDeviceGene therapyOptogenetics-based gene therapy
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Kubota Vision.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kubota Vision.